Search results for "COMBINATION"

showing 10 items of 1379 documents

The study of time-resolved absorption and luminescence in PbWO4 crystals

2000

Abstract The transient absorption and luminescence under pulsed electron beam excitation were studied for undoped and La3+ doped PbWO4 crystals. The absorption band at ∼1.0 eV is suggested to be due to self-trapped electrons and the absorption band at 3.5 eV may be due to self-trapped holes. The formation of luminescence centers via electron–hole recombination is affected by La3+ in doped crystals. The large fraction of electrons and holes undergoes thermostimulated recombination within geminate pairs and the spatial separation of geminate pairs components is important in recombination process. The intrinsic (blue) luminescence arises in this recombination. The mechanism of La3+ influence o…

inorganic chemicalsNuclear and High Energy PhysicsAbsorption bandChemistryUltrafast laser spectroscopyDopingElectronAtomic physicsAbsorption (electromagnetic radiation)LuminescenceInstrumentationRecombinationExcitationNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
researchProduct

Role of Nutraceuticals in Hypolipidemic Therapy.

2015

Nutraceuticals are food components or active ingredients present in foods and used in therapy. This article analyzes the characteristics of the molecules with a lipid-lowering effect. The different nutraceuticals may have different mechanisms of action: inhibition of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase (policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols, probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul). Based on the different mechanisms of action, some nutraceuticals are then abl…

lcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaCombination therapyPharmacologyCardiovascular Medicinelipidschemistry.chemical_compoundNutraceuticalBerberinelipidRed yeast riceReviews in MedicineMedicineLDL-cholesterolPolicosanolActive ingredientnutraceuticalsbusiness.industrycardiovascular preventionClinical trialchemistrylcsh:RC666-701Intestinal cholesterol absorptionhypolipidemic therapynutraceuticalCardiology and Cardiovascular Medicinebusinessmedicine.drugFrontiers in cardiovascular medicine
researchProduct

Risk assessment of information on the subcombination Bt11 × 1507 × GA21, related to the application of Syngenta (EFSA‐GMO‐DE‐2011‐99) for authorisati…

2017

Efsa Panel On Genetically Modified Organisms (gmo)StatementRequestor: European CommissionQuestion number: EFSA-Q-2016-00730; The EFSA Panel on Genetically Modified Organisms (GMO) has previously assessed the single events Bt11, MIR162, MIR604 and GA21 as well as different stacked events corresponding to combinations of these events. These maize events were found to be as safe as their conventional counterparts and other appropriate comparators with respect to potential effects on human and animal health and the environment. In its assessment of the four-event maize stack Bt11 9 MIR162 9 MIR604 9 GA21, the GMO Panel also assessed all the subcombinations of these events not previously assesse…

maïsVeterinary (miscellaneous)gmo[SDV]Life Sciences [q-bio]ogmPlant ScienceTP1-1185010501 environmental sciencessubcombination Bt11 x 1507 x GA21maize01 natural sciencesMicrobiologyzea maysfive‐event maize stack Bt11 × 59122 × MIR604 × 1507 × GA210404 agricultural biotechnologyTX341-641GMO;maize (Zea mays);Regulation (EC) No 1829/2003;subcombination Bt11 x 1507 x GA21;five-event maize stack Bt11 x 59122 x MIR604 x 1507 x GA21maize (Zea mays)Bt11 9 MIR162 9 MIR604 9 GA210105 earth and related environmental sciences2. Zero hungerNutrition. Foods and food supplyindian cornChemical technologyRegulation (EC) No 1829/2003maize (Zea mays)04 agricultural and veterinary sciencesfour-event maize stack040401 food sciencesubcombination Bt11 × 1507 × GA21Animal Science and ZoologyParasitologysubcombination Bt11 9 MIR162Statementfive-event maize stack Bt11x 59122 x MIR604 x 1507 x GA21Food ScienceRegulation (EC) No 1829/2003
researchProduct

An operatorial approach to stock markets

2009

We propose and discuss some toy models of stock markets using the same operatorial approach adopted in quantum mechanics. Our models are suggested by the discrete nature of the number of shares and of the cash which are exchanged in a real market, and by the existence of conserved quantities, like the total number of shares or some linear combination of cash and shares. The same framework as the one used in the description of a gas of interacting bosons is adopted.

media_common.quotation_subjectGeneral Physics and AstronomyStatistical and Nonlinear Physicsoperatorial approachConserved quantitystock marketFOS: Economics and businessCashQuantitative Finance - General FinanceGeneral Finance (q-fin.GN)Linear combinationSettore MAT/07 - Fisica MatematicaMathematical economicsMathematical PhysicsStock (geology)media_commonBosonMathematicsJournal of Physics A: Mathematical and General
researchProduct

Exclusion of Saccharomyces kudriavzevii from a wine model system mediated by Saccharomyces cerevisiae.

2010

This study investigated the competition and potential hybrid generation between the species Saccharomyces cerevisiae and S. kudriavzevii in a wine-model environment. Our main goal was to understand why S. kudriavzevii has not been found in wine fermentations whilst their hybrids are present. Auxotrophic mutants (Ura(-) and Lys(-)) were used to favour the selection of hybrids and to specifically differentiate the two species in mixed fermentations carried out at different temperatures (17 °C, 24 °C and 31 °C). Both yeasts showed a reduction in their maximum specific growth rates in mixed fermentations, indicating a clear antagonistic effect between the two microorganisms. Temperature played …

media_common.quotation_subjectPopulationSaccharomyces cerevisiaeBioengineeringWineApplied Microbiology and BiotechnologyBiochemistrySaccharomycesCompetition (biology)SaccharomycesBotanyAntibiosisGeneticsFood scienceSelection Geneticeducationmedia_commonWineFermentation in winemakingRecombination Geneticeducation.field_of_studybiologyEthanolTemperaturefood and beveragesbiology.organism_classificationGrowth InhibitorsFermentationFermentationSaccharomyces kudriavzeviiBiotechnologyYeast (Chichester, England)
researchProduct

Combined oral prolonged-release oxycodone and naloxone in chronic pain management

2013

Introduction: The use of opioids is associated with unwanted adverse effects, particularly opioid-induced constipation (OIC). The adverse effects of opioids on gastrointestinal function are mediated by the interaction with opioid receptors in the gastrointestinal tract. The most common drugs used for relieving OIC are laxatives, which do not address the opioid receptor-mediated bowel dysfunction and do not provide sufficient relief. Areas covered: This paper discusses the role of a combination of prolongedrelease formulation of oxycodone (OX) and naloxone (N) in the prevention and management of OIC, reporting efficacy and safety outcome of controlled studies. In a therapeutic area of great …

medicine.drug_classSettore MED/41 - Anestesiologiacancer pain chronic pain opioid-antagonist opioids oxycodone--naloxone combinationNaloxonemedicineHumansPharmacology (medical)Adverse effectPharmacologybusiness.industryNaloxoneChronic painGeneral Medicinemedicine.diseaseAnalgesics OpioidDrug CombinationsTreatment OutcomeOpioidAnesthesiaDelayed-Action PreparationsChronic PainGastrointestinal functionbusinessCancer painOxycodoneOpioid antagonistOxycodonemedicine.drug
researchProduct

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ?

2009

Ezetimibe represents the first of a new class of agents, the cholesterol absorption inhibitors, able to reduce low-density lipoproteins (LDL)-cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. To-date all the data regarding the efficacy of ezetimibe comes from the studies of its lipid-lowering power. Yet, recent findings from the ENHANCE study on atherosclerosis progression showed that the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolemia did not affect the mean change in carotid intima-media thickness, although a significant reduction in LDL-cholesterol levels was present. Therefore, we cannot exclude that e…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthFamilial hypercholesterolemiaBioinformatics2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundEzetimibePredictive Value of TestsInternal medicinemedicineAnimalsHumansProspective cohort studyCardiovascular risk Cholesterol LDL size Small dense LDLDyslipidemiasEzetimibe LDL-cholesterolCholesterolVascular diseasebusiness.industryAnticholesteremic AgentsHypertriglyceridemiaReproducibility of ResultsCholesterol LDLEzetimibemedicine.diseaseTreatment OutcomeEndocrinologychemistrySimvastatinAzetidinesDrug Therapy Combinationlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersDyslipidemiamedicine.drug
researchProduct

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.

2021

Abstract Aims Peripheral artery disease (PAD) patients suffer a high risk of major cardiovascular (CV) events, with athero-thrombo-embolism as the underlying pathophysiologic mechanism. Recently, two large randomized clinical trials evaluated the efficacy and safety of low-dose rivaroxaban twice daily plus aspirin in stable PAD outpatients and those immediately after peripheral revascularization. We sought to determine if the effects of low-dose rivaroxaban and aspirin compared to aspirin alone are consistent across this broad spectrum of PAD patients. Methods and results We conducted a random-effects meta-analysis of the COMPASS and VOYAGER randomized trials among 11 560 PAD patients (4996…

medicine.medical_specialtyAcute limb ischaemiaEpidemiologymedicine.medical_treatmentHemorrhageRevascularizationlaw.inventionBrain IschemiaPeripheral Arterial DiseaseRandomized controlled trialFibrinolytic AgentsRivaroxabanlawIschemiaInternal medicineMedicineHumansMyocardial infarctionAspirinRivaroxabanAspirinbusiness.industryHazard ratiomedicine.diseaseStrokeAmputationCardiologyDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsEuropean journal of preventive cardiology
researchProduct

Is there a role for antileukotrienes in urticaria?

2006

In vitro and in vivo clinical and experimental data have suggested that leukotrienes play a key role in inflammatory reactions of the skin. Antileukotriene drugs, i.e. leukotriene receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory drugs that have shown clinical efficacy in the management of asthma. We searched the MedLine database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective in chronic urticaria associated with aspirin or food additive hypersensitivity or with autoreactivity to intradermal serum injection when taken with an antihistamine b…

medicine.medical_specialtyAllergyLeukotrienesSettore MED/09 - Medicina InternaUrticariamedicine.medical_treatmentDermatologyCold urticariaimmune system diseasesparasitic diseasesmedicineHumansZafirlukastskin and connective tissue diseasesMontelukastAsthmaClinical Trials as TopicAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalZileutonmedicine.diseaseDermatologyAntileukotrieneantileukotrieneantileukotrienes; urticariaHistamine H1 AntagonistsLeukotriene AntagonistsAntihistamineDrug Therapy CombinationFood Additivesbusinessmedicine.drugClinical and experimental dermatology
researchProduct

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management…

2020

Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg). Methods A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infect…

medicine.medical_specialtyAllergySettore MED/12 - GASTROENTEROLOGIAallergicPenicillinsGastroenterologyHelicobacter InfectionsDrug Hypersensitivity03 medical and health sciences0302 clinical medicineLevofloxacinMetronidazoleClarithromycinInternal medicinebismuthmedicineHumansProspective StudiesRegistriesAdverse effectlevofloxacinbiologyHelicobacter pyloribusiness.industrySettore MED/09 - MEDICINA INTERNAallergic ; allergy ; bismuth ; clarithromycin ; Helicobacter pylori ; levofloxacin ; penicillinGastroenterologyProton Pump InhibitorsGeneral MedicineTetracyclineHelicobacter pyloribiology.organism_classificationmedicine.diseaseallergyclarithromycinAnti-Bacterial Agents3. Good healthPenicillinMetronidazoleRegimenInfectious Diseasespenicillin030220 oncology & carcinogenesisDrug Therapy Combination030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct